Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, which may be the consequence of inflammation and oxidative stress that ultimately leads to a reduced nitric oxide (NO) bioavailability. Passive leg movement (PLM) is a novel methodology for assessing lower limb vascular function that is predominantly NO dependent. We combined this vascular assessment with a comprehensive panel of plasma biomarkers to assess the axis of inflammation, oxidative stress and NO in SSc patients (n = 12; 62 ± 11 years of age) compared with healthy control subjects (n = 17; 60 ± 16 years of age). The PLM-induced changes in leg blood flow (LBF;
INTRODUCTION
Systemic sclerosis (SSc) is a multisystem disorder characterized by autoimmunity, tissue fibrosis and pronounced vasculopathy and is often associated with increased inflammation and oxidative stress.
Vasculopathy is an early and important component of SSc and has clinical presentations that include Raynaud's phenomenon (RP), which is often the initial indicator of the disease, and digital ulcers (DU), pulmonary arterial hypertension (PAH) and scleroderma renal crisis
New Findings
• What is the central question of this study? Do systemic sclerosis patients exhibit impaired nitric oxide-mediated vascular function of the lower limb and are these decrements correlated with plasma biomarkers for inflammation and oxidative stress?
• What is the main finding and its importance?
Findings indicate impaired nitric oxide-mediated vascular function, linked to the incidence of digital ulcers and a milieu of inflammation and oxidative stress. However, the absence of significant correlations between individual biomarkers and blood flow responses suggests that the vasculopathy observed in systemic sclerosis may not be solely the result of derangements in the redox balance or inflammatory signalling.
investigated the degree to which vascular function is impaired in SSc by means of flow-mediated dilatation (FMD) and have reported that FMD is attenuated in SSc patients compared with healthy control subjects. Moreover, within the SSc population, FMD has been documented to be attenuated further with disease duration (Takahashi et al., 2014) , increasing severity of microvascular changes (Rollando et al., 2010) , and in those with a history of DU (Frech et al., 2015) . Flowmediated dilatation has thus been well established as a method for assessing vascular health. However, recent studies using the endothelial nitric oxide synthase (eNOS) inhibitor N G -monomethyl-Larginine have challenged FMD as a bioassay for NO, finding modest (Wray et al., 2013) to no difference (Pyke et al., 2010) in the postocclusion vasodilatory response in the presence of this inhibitor, thus questioning the magnitude of the contribution of NO to the FMD response. In light of this, our group developed the passive leg movement (PLM) test as an alternative, non-invasive method for assessing NO-mediated vascular function. The hyperaemic response to PLM has been documented to be predominantly NO mediated (Groot et al., 2015b; Mortensen, Askew, Walker, Nyberg, & Hellsten, 2012; Trinity et al., 2012) , and although this technique has been used to describe decrements in NO-mediated vascular function with ageing (Groot et al., 2013 (Groot et al., , 2015a Mortensen et al., 2012) and disease states such as peripheral artery disease (Mortensen et al., 2012) , heart failure (Witman et al., 2015) and sepsis (Nelson et al., 2016) , it has not yet been used to characterize the extent to which NO-mediated vascular function may be impaired in SSc. In addition to being NO dependent, the PLM response reflects vasodilatation of the feed arteries and microvascular beds, further distinguishing it from FMD, which assesses conduit artery dilatation. Moreover, this test specifically interrogates vascular function in the leg. To date, vascular function assessments in SSc have been performed largely in the arm, despite clinical vascular complications being reported in both the upper and lower limbs.
Passive leg movement testing thus provides the opportunity to extend previous studies in SSc (Bartoli et Szűcs et al., 2007; Takahashi et al., 2014) and offer new insight into the nature and degree of lower limb vascular dysfunction in this unique patient population.
Therefore, the purpose of this investigation was to combine plasma biomarkers of inflammation, antioxidant capacity and oxidative stress with a novel assessment of NO bioavailability to evaluate the mechanisms contributing to the vascular pathophysiology in SSc patients. We hypothesized that the PLM-induced hyperaemic response would be attenuated in SSc compared with that of healthy control subjects and that this would be accompanied by elevated systemic inflammation, impaired antioxidant capacity and greater oxidative stress in these patients. An additional aim of this study was to evaluate the relationship between the PLM response in SSc and the incidence of DU, an important clinical cardiovascular end-point, with the hypothesis that patients with a history of DU would demonstrate a greater impairment in vascular function than those without DU.
METHODS

Ethical approval
The experimental protocol was approved by the University of Utah and Salt Lake City VA Medical Center Institutional Review Board (IRB_00040212) and was in compliance with clause 35 of the Declaration of Helsinki, except for registration in a database. All participants gave written informed consent.
Participants
Twelve SSc patients and 17 healthy, age-matched control subjects were recruited through the University of Utah SSc Clinic or the Utah Vascular Research Laboratory (UVRL). All participants were nonsmokers and were normally active. Patients met classification criteria for a diagnosis of SSc (van den Hoogen et al., 2013) . Female participants who were premenopausal were studied during the follicular phase of the menstrual cycle. All participants abstained from exercise, alcohol and caffeine for 24 h before the study visit and were ≥5 h postprandial.
The SSc patients abstained from any vasoactive medications for 12 h before the study visit, as directed by their physician. All data collection took place at the UVRL located in the Salt Lake City VA Medical Center's Geriatric Research, Education and Clinical Center.
Passive leg movement protocol and measurements
Patients were instrumented and rested quietly in a thermoneutral room in the supine position for ≥15 min before the start of PLM.
After 1 min of baseline measures, PLM was performed by a trained investigator who moved the patient's knee joint from 180 deg (full extension) to 90 deg at a rate of 1 Hz continuously for 2 min. Patients were instructed to remain passive and not resist or assist with the movement. To avoid a startle reflex, patients were made aware that PLM would start in 5-10 s, but to avoid an anticipatory response they were not made aware of exactly when the movement would begin. 
Inflammation, antioxidant capacity and oxidative stress
Venous blood samples were obtained at the beginning of the study visit and were centrifuged to collect plasma. These samples were then stored at −80 • C until analysis. Plasma concentrations of tumour necrosis factor-(TNF ), interleukin-6 (IL-6), and C-reactive protein (CRP) were determined using high-sensitivity enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). Plasma free radical concentrations were directly assessed by spin trapping and electron paramagnetic resonance (EPR) spectroscopy. Briefly, 3.0 ml of venous blood was collected into a vacutainer containing 1.0 ml -phenyl-tert-butylnitrone (PBN; 0.14 M), then the PBN adduct was extracted under toluene and pipetted into a precisionbore quartz EPR spectroscopy sample tube (Wilmad-LabGlass, Vineland, NJ, USA) that had been flushing with compressed N 2 .
The EPR spectroscopy was performed at 21 • C with an EMX Xband spectrometer (Bruker, Billerica, MA, USA) and analysed with commercially available software (Bruker Xenon, version 1.1b.51), with the analyst blinded to experimental conditions, and reported as PBN adduct in arbitrary units (a.u.). Total antioxidant capacity was determined by the ferric reducing ability of plasma (FRAP) using the method previously described by Benzie & Strain (1996) . The activity of superoxide dismutase (SOD), an important endogenous antioxidant that scavenges superoxide and spares NO, was assessed by colorimetry (Cayman Chemical Company, Ann Arbor, MI, USA). Lipid peroxidation was assessed by malondialdehyde (MDA) concentrations using colorimetry (Bioxytech MDA-586 assay; OxisResearch, Burlingame, CA, USA), and protein oxidation was assessed by plasma protein carbonyl (PC) concentrations using colorimetry (PC test kit; Biocell Corporation LTD, Papatoetoe, New Zealand).
Statistics
Physical characteristics, resting cardiovascular measures, PLMinduced blood flow responses and plasma biomarkers were compared between groups [control (CON) versus SSc and DU versus non-DU] using Student's unpaired t tests to identify any group differences.
When comparing DU and non-DU groups with CON, ANOVA was used, and post hoc testing was performed using the Tukey test when main effects were found. The Pearson correlation coefficient test was used to assess relationships between plasma biomarkers and PLM responses and between baseline LBF and PLM responses. Significance was set at P < 0.05, and data are expressed as means ± SD.
RESULTS
Participants
The SSc patients and control subjects were well matched for sex, age, height, weight and body mass index (Table 1) . Disease-specific characteristics and pharmacological therapeutic information for the SSc patients are documented in Table 2 . Among the patient population, SSc disease duration and duration since onset of RP symptoms both ranged from 1 to 36 years, with a mean of 9.6 and 10.0 years, respectively (Table 2) . Of the 12 patients, three had prescriptions for cardiovascular medications at the time of the study, which included calcium channel blockers, angiotensin receptor blockers and diuretics.
All SSc patients were positive for antinuclear antibodies, and a slight majority (58%) were positive for anticentromeric antibodies. Twothirds of the patients were identified as having limited SSc, whereas the remaining one-third was identified as having the diffuse phenotype.
Half of the SSc patients had a history of DU.
TA B L E 1 Characteristics of SSc patients and healthy control subjects
Characteristic
Control (n = 17) SSc (n = 12)
Age (years) 60 ± 16 62 ± 11
Height (cm) 167 ± 9 169 ± 9
Weight (kg) 72.7 ± 12.2 71.4 ± 11.6
Values are means ± SD. Abbreviations: BMI, body mass index; and SSc, systemic sclerosis. There were no significant differences between the groups.
TA B L E 2 Systemic sclerosis patient health history and medication use
SSc disease duration (years) 9.6 ± 9.9 RP duration ( Values are means ± SD. Abbreviations: CVD, cardiovascular disease; DU, digital ulcer; ERA, endothelin receptor antagonist; PAH, pulmonary arterial hypertension; PDE5I, phosphodiesterase 5 inhibitor; RP, Raynaud's phenomenon; SCL70, anti-Scl-70 antibody; and SRC, scleroderma renal crisis.
Baseline measurements
At rest, HR, MAP and femoral artery diameter were not different between control subject and patients, nor were there any differences between patients with a history of DU and those without ( Table 3) .
As a group, SSc patients had higher V mean , LBF and anterograde LBF than control subjects. Correlation analysis failed to identify a significant relationship between baseline LBF and peak change in LBF (r 2 = 0.031, P = 0.363) or LBF AUC (r 2 = 0.007, P = 0.675). There were no differences in any baseline measurements between patients with and without DU.
Response to passive leg movement
Passive leg movement elicited a hyperaemic response in both control subjects and SSc patients (Figure 1a) . The AUC for this response was ∼69% lower in SSc (Figure 1b) , and this was largely attributable to a ∼51% attenuation in anterograde LBF AUC (Figure 1d ). Retrograde LBF AUC differences were not significant (Figure 1f ). When assessed as the change in LBF, the SSc PLM response was notably different from that of control subjects, and the peak change in LBF was ∼42% lower than in control subjects (Figure 2 ).
Inflammation, antioxidant capacity and oxidative stress
There were no differences between groups in the pro-inflammatory cytokines TNF (1.52 ± 0.72 versus 1.12 ± 0.59 pg ml −1 , CON versus SSc) or IL-6 (1.55 ± 1.71 versus 2.14 ± pg ml −1 , CON versus SSc), but systemic inflammation, as assessed by CRP, was greater in the SSc group (984 ± 565 versus 3299 ± 2372 ng ml −1 , CON versus SSc; Figure 3 ). Plasma free radical concentrations, as assessed by EPR spectroscopy, were not different between control subjects and patients (6.9 ± 7.4 versus 10.4 ± 9.7 a.u., CON versus SSc; Figure 4 ). FRAP, a measure of total antioxidant capacity, was elevated in SSc (1.2 ± 0.46 versus 2.2 ± 1.0 mM, CON versus SSc), whereas SOD, a measure of endogenous antioxidant capacity, was lower (12.1 ± 4.2 versus 8.8 ± 4.1 U ml −1 , CON versus SSc; Figure 5 ). Lipid peroxidation, as determined by plasma MDA, was increased in SSc patients (1.1 ± 0.7 versus 3.2 ± 1.1 M, CON versus SSc; Figure 6 ).
Likewise, protein oxidation, as assessed by plasma PC, was also elevated in the SSc group (0.12 ± 0.03 versus 0.15 ± 0.05 nmol mg −1 , CON versus SSc; Figure 6 ). There were no significant correlations between any biomarkers and either LBF AUC or peak change in LBF,
TA B L E 3 Resting cardiovascular measurements
Parameter Control SSc (n = 17) All (n = 12) No DU (n = 6) DU (n = 6) HR (beats min −1 ) 6 1 ± 11 67 ± 10 66 ± 11 68 ± 10 MAP (mmHg) 92 ± 13 84 ± 7 82 ± 8 86 ± 6 FA diameter (cm) 0.86 ± 0.15 0.80 ± 0.12 0.74 ± 0.10 0.87 ± 0.10
Vel. (cm s −1 ) 8.9 ± 3.4 14.8 ± 7.9* 16.9 ± 9.6* 12.7 ± 6.1 LBF (ml min −1 ) 299 ± 94 418 ± 140* 412 ± 182 424 ± 100
Anterograde LBF (ml min −1 ) 402 ± 81 516 ± 143* 502 ± 180 531 ± 109
Retrograde LBF (ml min −1 ) 104 ± 49 99 ± 63 90 ± 57 107 ± 72
Values are means ± SD. Abbreviations: DU, history of digital ulcers; FA, femoral artery; HR, heart rate; LBF, leg blood flow; MAP, mean arterial pressure; No DU, no history of digital ulcers; SSc, systemic sclerosis; and Vel., blood velocity. * Significantly different from control group (P < 0.05). 
Digital ulcers, PLM responses and inflammation markers
Systemic sclerosis patients with a history of DU demonstrated markedly attenuated LBF AUC in response to PLM compared with patients who had no incidence of DU (Figure 7a ), which may be attributed in large part to a ∼155% greater retrograde blood flow in the DU group (Figure 7d ). There were no significant differences in inflammation, antioxidant capacity and oxidative stress biomarkers between patients with and without a history of DU, with the exception of CRP, which was ∼122% greater in patients with DU (Table 4) .
However, CRP concentrations were not predictive of peak change in LBF (r 2 = 0.06, P = 0.43) or LBF AUC (r 2 = 0.08, P = 0.39) in SSc patients.
Time ( 
Response to PLM in SSc
To provide better characterization of the vascular dysfunction in Witman et al., 2015) . Indeed, our group recently reported strikingly similar results to those seen here in SSc in a group of patients with severe sepsis (Nelson et al., 2016) . In this previous study, we speculated that the attenuated PLM response was likely to be the result of a combination of vascular insensitivity to shear stress from upregulation. In SSc, there is also evidence of a downregulation of eNOS and upregulation of iNOS (Cotton, Herrick, Jayson, & Freemont, 1999; Yamamoto, Katayama, & Nishioka, 1998) and an overproduction of NO (Devrim et al., 2008; Luo, Liu, Jiang, Zhao, & Zhao, 2017; Mok et al., 2008; Yamamoto et al., 1998) , making the dysregulation of NO signalling from eNOS and iNOS a likely culprit for the attenuated vascular responsiveness in this patient group.
Inflammation, oxidative stress and antioxidant capacity in SSc
The PLM response is largely mediated by NO bioavailability (Groot et al., 2015b; Mortensen et al., 2012; Trinity et al., 2012) , which in turn is strongly influenced by the presence of oxidative stress.
Indeed, oxidative stress attenuates NO bioavailability by both decreasing NO production, predominantly by uncoupling eNOS (Landmesser et al., 2003) , and increasing NO degradation, namely through its conversion to peroxynitrite by superoxide (Ferrer-Sueta & Radi, 2009) . Moreover, uncoupled eNOS will produce superoxide rather than NO, and the elevated concentrations of superoxide will then go on to degrade existing pools of NO, further attenuating NO bioavailability. Indeed, elevated levels of oxidative stress are often associated with impairments in NO signalling and endothelial function, and studies aimed at lowering oxidative stress through antioxidant supplementation have reported improvements in endothelial function (Ives et al., 2014; Witman et al., 2012; Wray et al., 2012) . Thus, to explore potential mechanisms responsible for the observed decrement in NO-mediated PLM responses in SSc patients,
we assessed an extensive panel of biomarkers specific for systemic inflammation, oxidative stress and total/endogenous antioxidant capacity. The rationale for evaluating these biomarkers is related to the pathogenesis of SSc, as it has been proposed that after an initial if inflammation leads to oxidative stress (Fuschiotti, 2016; Gabrielli et al., 2012; Incalza et al., 2018; Matucci-Cerinic et al., 2013) . However, although the seminal event remains elusive, it is evident that both inflammation and oxidative stress contribute significantly to the progression of the disease.
Surprisingly, the two pro-inflammatory cytokines measured in this study, TNF and IL-6, were not significantly different between SSc patients and the healthy control subjects (Figure 3a and b).
Although this differs from some previously reported findings (Hussein et al., 2005; Pehlivan et al., 2012) , these former studies examined individuals who were notably younger, with mean ages in the 30s and 40s, compared with the present study with a mean age in the 60s. As ageing per se is associated with increased expression of both TNF and IL-6 (Donato, Black, Jablonski, Gano, & Seals, 2008), the advanced age of both the SSc and control groups here might have diminished the ability to detect disease-specific differences in these biomarkers. Additionally, these previous studies also failed to report medication use, which is important given the known ability of immunosuppressive and antihypertensive pharmacotherapy to reduce circulating concentrations of TNF and IL-6 (Toledo et al., 2015) . In the present study, several SSc patients were on immunosuppressive or antihypertensive medications, which might have exerted antiinflammatory effects. However, despite the lack of evidence for an elevation in the pro-inflammatory cytokines TNF and IL-6, CRP was elevated in SSc patients compared with control subjects (Figure 3c which is consistent with previous studies in this patient group (Cypiene et al., 2008) . Although these biomarkers represent major players in the inflammatory cascade, inflammation is the result of a shift in the complex balance of both pro-and anti-inflammatory cytokines. Together, these findings suggest that there is some degree of derangement in the inflammatory profile of patients with SSc compared with their age-matched control subjects.
Perhaps related to this increase in inflammation, we observed a markedly higher resting LBF in SSc patients compared with their age-matched counterparts (Table 3 ). This seems contrary to what would be expected in SSc, as these patients are typically characterized by severely compromised blood flow in the peripheral circulation, particularly the digital arteries. Our group has previously reported that resting blood flow through the brachial artery is preserved in SSc (Frech et al., 2015) , but resting blood flow in the femoral artery has not been well described. Interestingly, we also observed an elevation in resting LBF in sepsis patients (Nelson et al., 2016) that was no longer present at a 3 day follow-up, probably because of a subsidence of the initial inflammatory response. Given that inflammation is considered a key component in the pathophysiology of SSc (Fuschiotti, 2016) , TA B L E 4 Markers of inflammation, oxidative capacity and oxidative stress in systemic sclerosis patients with and without a history of digital ulcers
Marker
No DU (n = 6) DU (n = 6) TNF (pg ml −1 ) 0 . 9 ± 0.5 1.4 ± 0.6 IL-6 (pg ml it is conceivable that aspects of the inflammatory cascade could be contributing to this paradoxical increase in resting LBF in the present study.
Although the plasma free radical concentrations (as assessed by EPR spectroscopy) were not different between groups (Figure 4 ), FRAP, a measure of the total antioxidant capacity and marker of antioxidant system activation, was greater in SSc patients (Figure 5a ).
Previous studies that used this same assay found total antioxidant capacity to be slightly, but not significantly, higher in patients with SSc compared with healthy control subjects. This observation was contrary to the expected diminution in total antioxidant capacity in these patients, and the authors speculated that these findings might be explained by enhanced antioxidant production in response to the elevated levels of ROS (Firuzi et al., 2006; Riccieri et al., 2008) .
Likewise, a study using the copper-reducing ability of serum to assess total antioxidant power found this to be significantly greater in SSc and, like the aforementioned studies, suggested that this was an indicator of a global response to the oxidative stress associated with SSc (Ogawa, Shimizu, Muroi, Hara, & Sato, 2011) . Although our findings of elevated FRAP also suggest a generalized response to oxidative challenges in this patient group, a specific endogenous antioxidant enzyme, SOD, was significantly lower in SSc (Figure 5b) , which is consistent with other findings (Luo et al., 2017) . Taken together, these data suggest that although the global response to oxidative stress may be elevated in patients with SSc, some of their endogenous capacity to deal with oxidative stress may be compromised.
Markers of oxidative damage were greater in the SSc patients.
Malondialdehyde, a byproduct of lipid peroxidation, was elevated in SSc patients (Figure 6a ), which is in agreement with several studies reporting evidence of lipid peroxidation through MDA (Devrim et al., 2008; Luo et al., 2017) and peroxide levels (Firuzi et al., 2006; Luo et al., 2017; Riccieri et al., 2008) in this population. We also observed that protein oxidation, indicated by PC, was elevated in SSc (Figure 6b) , although some earlier studies did not detect any differences (Firuzi et al., 2006; Riccieri et al., 2008) . Although direct assessment of plasma free radical concentration (EPR spectroscopy) did not reveal differences between groups, elevated MDA and PC suggest a cumulative effect of intermittent bouts of oxidative stress that produce a footprint of oxidative damage in these patients, in spite of greater total antioxidant capacity (as measured by FRAP).
Responses to PLM in DU versus non-DU patients
Digital ulcers are a debilitating vascular complication in SSc, and a history of DU is associated with more rapid disease progression and increased risk of cardiovascular events and mortality (Mihai et al., 2016) . Although the aetiology of DU formation remains incompletely understood, it is likely that disease-related alterations in vascular function may play a crucial role. Indeed, our group has previously reported that SSc patients with a history of DU demonstrate impaired endothelium-dependent vasodilatation, as assessed by FMD, compared with their non-DU SSc counterparts (Frech et al., 2015) . (Hwang et al., 2003; Schreuder, Green, Hopman, & Thijssen, 2014; Ziegler, Bouzourène, Harrison, Brunner, & Hayoz, 1998) . However, in this case we are unable to determine whether having a more severe manifestation of the disease is causing the greater retrograde blood flow, or if greater retrograde blood flow in these patients results in the disease following a more deleterious path. Interestingly, plasma markers of inflammation were more than twofold higher in DU versus non-DU patients (Table 4) , providing further support that this group has a more severe manifestation of the disease. Given the clinical importance of DU, further studies to determine whether PLM testing might be of prognostic relevance in predicting the development of DUs, as previously demonstrated for FMD (Frech et al., 2015) , are warranted.
Limitations
The PLM response is reported as the peak change in LBF from baseline and as the LBF AUC normalized to baseline, which accounts for differences in baseline femoral artery blood flow across different populations. Although we cannot exclude the possibility that differences in resting LBF in the present study might have influenced PLM responses, this concern is mitigated by the lack of correlation between baseline LBF and both peak change in LBF and LBF AUC.
Our group and others have demonstrated that NOS inhibition by N G -monomethyl-L-arginine administration reduces, but does not completely abolish, the PLM response (Groot et al., 2015b; Mortensen et al., 2012; Trinity et al., 2012) , suggesting that other vasodilators might contribute to the hyperaemic response. We therefore cannot exclude the possibility that the reduced PLM response observed in SSc patients might also be attributable to disease-related changes in non-NO vasodilator pathways. Additionally, it is noteworthy that SSc patients demonstrate structural remodelling of the vasculature, including narrowing or occlusion of small arteries (Lüders et al., 2017) and changes in capillary morphology and density (Pizzorni et al., 2016) .
Given that PLM elicits vasodilatation of these smaller vessels and capillary beds, it is possible that these structural deformations might be limiting, at least in part, the ability of SSc patients to augment blood flow in response to passive movement. Further study is needed to determine whether the attenuated PLM response in SSc is a functional limitation arising from maladaptations in NO signalling, changes in other vasodilatory signalling mechanisms or is the result of structural limitations caused by luminal narrowing and capillary rarefication.
Conclusions
The hyperaemic response to PLM is significantly attenuated in SSc, 
